VISTN — Vistin Pharma ASA Income Statement
0.000.00%
Last trade - 00:00
- NOK1.06bn
- NOK1.03bn
- NOK438.33m
- 89
- 40
- 74
- 79
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IFRS | — | — | — | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 227 | 253 | 276 | 288 | 438 |
Cost of Revenue | |||||
Gross Profit | 104 | 180 | 180 | 150 | 262 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 210 | 208 | 243 | 294 | 370 |
Operating Profit | 16.8 | 45.6 | 33.3 | -6.09 | 68.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 84 | -124 | 32 | -6.01 | 58.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 66.1 | -97 | 24.9 | -4.71 | 45.6 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 66.2 | -97 | 24.9 | -4.71 | 45.6 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 66.2 | -97 | 24.9 | -4.72 | 45.6 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.49 | -2.19 | 0.561 | -0.106 | 1.03 |
Dividends per Share | |||||
Special Dividends per Share |